Cerus Corp. Stock
Price
Target price
€1.57
€1.57
-2.700%
-0.043
-2.700%
€2.80
23.04.24 / Tradegate
WKN: 905249 / Symbol: CERS / Name: Cerus Corp / Stock / Healthcare Equipment & Supplies / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Cerus Corp. Stock
We can see a decrease in the price for Cerus Corp.. Compared to yesterday it has lost -€0.043 (-2.700%).
Currently there is a rather positive sentiment for Cerus Corp. with 3 Buy predictions and 0 Sell predictions.
With a target price of 2 € there is a positive potential of 27.8% for Cerus Corp. compared to the current price of 1.57 €.
Pros and Cons of Cerus Corp. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
B****
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cerus Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cerus Corp. | -2.700% | -0.761% | -11.231% | -31.118% | -26.179% | -68.700% | -69.290% |
| Orasure Tech | 2.410% | 2.049% | -14.138% | -22.791% | -33.154% | -38.412% | -40.622% |
| scPharmaceuticals | 2.830% | 1.435% | -13.115% | -51.818% | -26.261% | -22.909% | - |
| SI-BONE Inc | -2.780% | 1.408% | 2.128% | -27.638% | -24.211% | -49.650% | - |
Comments
Cerus Co. (NASDAQ: CERS) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $5.00 price target on the stock.
Show more
Ratings data for CERS provided by MarketBeat
Cerus Co. (NASDAQ: CERS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $3.00 price target on the stock.
Show more
Ratings data for CERS provided by MarketBeat
Cerus Co. (NASDAQ: CERS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $3.00 price target on the stock, down previously from $9.00.
Show more
Ratings data for CERS provided by MarketBeat